[{"id":"2f59ed54-b06e-4d43-9212-6877b8a1fbe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470073","created_at":"2026-03-28T01:44:17.302Z","updated_at":"2026-03-28T01:44:17.302Z","phase":"Phase 1","brief_title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults","source_id_and_acronym":"NCT07470073","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-13"},{"id":"027ae0ad-75fc-4cbb-bdb2-326e57dba8b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07042438","created_at":"2025-07-05T14:03:14.313Z","updated_at":"2025-07-05T14:03:14.313Z","phase":"Phase 2","brief_title":"Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells","source_id_and_acronym":"NCT07042438","lead_sponsor":"City of Hope Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yescarta (axicabtagene ciloleucel)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 01/17/2026","start_date":" 01/17/2026","primary_txt":" Primary completion: 04/13/2028","primary_completion_date":" 04/13/2028","study_txt":" Completion: 04/13/2028","study_completion_date":" 04/13/2028","last_update_posted":"2025-06-29"},{"id":"2224e4ab-560d-46f1-b752-7b1d2154770f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04240808","created_at":"2021-01-18T20:37:11.481Z","updated_at":"2025-02-25T12:37:29.775Z","phase":"Phase 1","brief_title":"Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)","source_id_and_acronym":"NCT04240808","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD19","pipe":" | ","alterations":" CD19 positive","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCD19 CAR T Cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 03/24/2023","primary_completion_date":" 03/24/2023","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-24"},{"id":"e2019c9b-caf1-4a03-a256-ccdcd1f5cf7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06287528","created_at":"2024-03-01T19:33:07.907Z","updated_at":"2025-02-25T13:50:10.638Z","phase":"Phase 1","brief_title":"A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)","source_id_and_acronym":"NCT06287528","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" IL18","pipe":"","alterations":" ","tags":["IL18"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/23/2024","start_date":" 02/23/2024","primary_txt":" Primary completion: 02/23/2028","primary_completion_date":" 02/23/2028","study_txt":" Completion: 02/23/2028","study_completion_date":" 02/23/2028","last_update_posted":"2025-02-20"},{"id":"d5afe40d-858e-4e8c-a552-782c25a7e99d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834529","created_at":"2025-02-25T14:05:59.231Z","updated_at":"2025-02-25T14:05:59.231Z","phase":"Phase 1/2","brief_title":"CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT06834529","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/20/2025","start_date":" 01/20/2025","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-19"},{"id":"ea26acb5-1d9c-43f2-bde5-b6e08ca13bd7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554939","created_at":"2022-09-26T14:56:16.908Z","updated_at":"2025-02-25T14:09:09.767Z","phase":"Phase 1/2","brief_title":"Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL","source_id_and_acronym":"NCT05554939","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" CD19 positive • Chr t(11;14)","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Mustargen (mechlorethamine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/11/2022","start_date":" 12/11/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"8058c94b-0d21-42b2-b6cf-b07e05abfcb1","acronym":"PRO00037171","url":"https://clinicaltrials.gov/study/NCT04186520","created_at":"2021-07-05T17:26:53.958Z","updated_at":"2025-02-25T14:15:30.805Z","phase":"Phase 1/2","brief_title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","source_id_and_acronym":"NCT04186520 - PRO00037171","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-20/19-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"b247da14-d5e7-4fb2-affb-37741374b540","acronym":"C402-001","url":"https://clinicaltrials.gov/study/NCT06830031","created_at":"2025-02-25T12:31:39.978Z","updated_at":"2025-02-25T12:31:39.978Z","phase":"Phase 1","brief_title":"Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma","source_id_and_acronym":"NCT06830031 - C402-001","lead_sponsor":"Shanghai Exuma Biotechnology Ltd.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 02/24/2025","start_date":" 02/24/2025","primary_txt":" Primary completion: 03/09/2026","primary_completion_date":" 03/09/2026","study_txt":" Completion: 05/11/2026","study_completion_date":" 05/11/2026","last_update_posted":"2025-02-17"},{"id":"2bded2d4-47b6-42ef-85b2-a3d47668df11","acronym":"BELINDA","url":"https://clinicaltrials.gov/study/NCT03570892","created_at":"2021-01-18T17:34:21.137Z","updated_at":"2025-02-25T14:39:57.185Z","phase":"Phase 3","brief_title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03570892 - BELINDA","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" ALK • BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["ALK • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 331","initiation":"Initiation: 05/07/2019","start_date":" 05/07/2019","primary_txt":" Primary completion: 05/06/2021","primary_completion_date":" 05/06/2021","study_txt":" Completion: 02/14/2026","study_completion_date":" 02/14/2026","last_update_posted":"2025-02-14"},{"id":"d02f7b2d-1c37-4780-a6b7-7db1aff0b46d","acronym":"PBCAR0191-01","url":"https://clinicaltrials.gov/study/NCT03666000","created_at":"2021-01-18T17:59:15.398Z","updated_at":"2025-02-25T15:10:55.408Z","phase":"Phase 1","brief_title":"Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL","source_id_and_acronym":"NCT03666000 - PBCAR0191-01","lead_sponsor":"Imugene Limited","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • azercabtagene zapreleucel (PBCAR0191) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 129","initiation":"Initiation: 03/11/2019","start_date":" 03/11/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-13"},{"id":"82e136f4-d38a-459f-8a3f-411cfccafc31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05495464","created_at":"2022-08-10T12:55:30.197Z","updated_at":"2025-02-25T15:00:33.482Z","phase":"Phase 1","brief_title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma","source_id_and_acronym":"NCT05495464","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5","pipe":" | ","alterations":" CD20 positive • Chr t(11;14)","tags":["TP53 • CD20 • CCND1 • KMT2D • NOTCH2 • BIRC3 • FAT1 • POT1 • NSD2 • UBR5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • fludarabine IV • Tecartus (brexucabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-12"},{"id":"961c39f5-982d-49c6-8dfa-778598f18be0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093841","created_at":"2023-10-23T20:14:00.026Z","updated_at":"2025-02-25T15:28:23.588Z","phase":"Phase 2","brief_title":"Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL","source_id_and_acronym":"NCT06093841","lead_sponsor":"Shanghai Ming Ju Biotechnology Co., Ltd.","biomarkers":" BCL2","pipe":" | ","alterations":" MYC rearrangement • BCL2 rearrangement","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Carteyva (relmacabtagene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 11/03/2023","start_date":" 11/03/2023","primary_txt":" Primary completion: 01/21/2024","primary_completion_date":" 01/21/2024","study_txt":" Completion: 11/04/2029","study_completion_date":" 11/04/2029","last_update_posted":"2025-02-11"},{"id":"c0f4d14f-2257-447f-847c-ebe3a10d55e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01087294","created_at":"2023-05-20T02:04:59.343Z","updated_at":"2025-02-25T15:32:08.685Z","phase":"Phase 1","brief_title":"Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation","source_id_and_acronym":"NCT01087294","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Completed","enrollment":" Enrollment 85","initiation":"Initiation: 08/04/2010","start_date":" 08/04/2010","primary_txt":" Primary completion: 03/08/2024","primary_completion_date":" 03/08/2024","study_txt":" Completion: 04/02/2024","study_completion_date":" 04/02/2024","last_update_posted":"2025-02-11"},{"id":"cf53eb98-b376-49ff-89cf-7b0f098f93c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06343090","created_at":"2024-04-02T20:42:22.091Z","updated_at":"2025-02-25T15:28:51.099Z","phase":"","brief_title":"Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients","source_id_and_acronym":"NCT06343090","lead_sponsor":"Beijing GoBroad Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"],"overall_status":"Recruiting","enrollment":" Enrollment 353","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 12/01/2042","primary_completion_date":" 12/01/2042","study_txt":" Completion: 09/30/2043","study_completion_date":" 09/30/2043","last_update_posted":"2025-02-11"},{"id":"818c72a5-92a4-43b8-8e83-ad27609f899b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05667506","created_at":"2022-12-28T16:01:43.670Z","updated_at":"2025-02-25T15:27:48.147Z","phase":"Phase 1/2","brief_title":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","source_id_and_acronym":"NCT05667506","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 02/07/2023","start_date":" 02/07/2023","primary_txt":" Primary completion: 07/30/2025","primary_completion_date":" 07/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-02-10"},{"id":"48054460-bb4c-4bdd-a42b-f1e76f7803ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586478","created_at":"2021-01-18T21:52:51.200Z","updated_at":"2025-02-25T16:32:17.231Z","phase":"Phase 2","brief_title":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT04586478","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Yorwida (inaticabtagene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-07"},{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"d7d0a6de-b0e3-4648-b4e9-ec298fd54104","acronym":"B-ALL","url":"https://clinicaltrials.gov/study/NCT06009107","created_at":"2024-03-13T08:35:11.520Z","updated_at":"2025-02-25T16:33:38.314Z","phase":"Phase 1/2","brief_title":"A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","source_id_and_acronym":"NCT06009107 - B-ALL","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 expression","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-02-07"},{"id":"52a20f08-fb55-44a8-b556-28ccbdd505e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05421663","created_at":"2022-06-16T15:00:08.321Z","updated_at":"2025-02-25T16:39:05.573Z","phase":"Phase 1","brief_title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05421663","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 12/29/2028","study_completion_date":" 12/29/2028","last_update_posted":"2025-02-06"},{"id":"7fd7343b-e00a-415f-aa0d-62ed50ea285e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02051257","created_at":"2021-01-18T09:25:59.407Z","updated_at":"2025-02-25T16:43:46.952Z","phase":"Phase 1","brief_title":"Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT02051257","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD28","pipe":" | ","alterations":" CD28 expression","tags":["CD28"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD28 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 CAR T cells"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/19/2014","start_date":" 06/19/2014","primary_txt":" Primary completion: 03/24/2025","primary_completion_date":" 03/24/2025","study_txt":" Completion: 03/24/2025","study_completion_date":" 03/24/2025","last_update_posted":"2025-02-06"},{"id":"5ed07491-b740-48b9-9e27-6d61db55c929","acronym":"","url":"https://clinicaltrials.gov/study/NCT03373071","created_at":"2021-01-18T16:38:50.176Z","updated_at":"2025-02-25T16:44:17.022Z","phase":"Phase 1/2","brief_title":"Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/refractory CD19+ ALL and NHL","source_id_and_acronym":"NCT03373071","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 12/23/2017","start_date":" 12/23/2017","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 01/24/2025","study_completion_date":" 01/24/2025","last_update_posted":"2025-02-05"},{"id":"3620a279-00d9-40e2-8835-c205c51f9360","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792633","created_at":"2021-01-18T18:45:04.269Z","updated_at":"2025-02-25T16:59:53.561Z","phase":"Phase 2","brief_title":"Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL","source_id_and_acronym":"NCT03792633","lead_sponsor":"University of Pennsylvania","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e huCART19"],"overall_status":"Completed","enrollment":" Enrollment 106","initiation":"Initiation: 01/18/2019","start_date":" 01/18/2019","primary_txt":" Primary completion: 04/04/2024","primary_completion_date":" 04/04/2024","study_txt":" Completion: 04/04/2024","study_completion_date":" 04/04/2024","last_update_posted":"2025-02-03"},{"id":"5721b478-7256-41e9-bdb4-f8b5fa921a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05418088","created_at":"2022-06-14T21:56:15.500Z","updated_at":"2025-02-25T17:01:57.164Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05418088","lead_sponsor":"Sumithira Vasu","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-03"},{"id":"71fc84c6-241a-4534-8cc7-be17409b90e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04276870","created_at":"2021-01-18T20:46:13.854Z","updated_at":"2025-02-25T17:30:11.424Z","phase":"Phase 2","brief_title":"Orphan Indications for CD19 Redirected Autologous T Cells","source_id_and_acronym":"NCT04276870","lead_sponsor":"Stephan Grupp MD PhD","biomarkers":" CD19 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • CD19 expression","tags":["CD19 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T)"],"overall_status":"Recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/12/2020","start_date":" 03/12/2020","primary_txt":" Primary completion: 03/10/2028","primary_completion_date":" 03/10/2028","study_txt":" Completion: 03/10/2037","study_completion_date":" 03/10/2037","last_update_posted":"2025-01-30"}]